Table 2.

Comparative analysis of the antiproliferative activity of mandelalide A to a panel of human non-small cell lung cancer (NSCLC) cells.

Cell Line	LKB1 Status	EGFR Status	GI50 (nM) ± SEM	TGI (nM) ± SEM
11-18	Loss	L848R	2.0 ± 0.4	174 ± 26
H460	Loss	WT	4.3 ± 0.6	50.2 ± 8.9
A549	Loss	WT	~300	>3000
H3122	WT	WT	4.7 ± 0.6	45.8 ± 13
H292	WT	WT	3.4 ± 0.2	51.5 ± 12
PC-9	WT	E746- A750 del	3.6 ± 0.7	133 ± 46

Human NSCLC cell lines with differing LKB1 and EGFR status were exposed to increasing concentrations of mandelalide A, or vehicle (0.1% DMSO), and the metabolic activity of the cultures was assessed at 72 h using an MTT assay. GI₅₀ and TGI values were determined by nonlinear regression analysis fit of the data to a logistic equation, with the viability of vehicle-treated control cells used to define 100% viability. Untreated cells assayed at the start of the study were used to define time = 0. Values represent the average of three independent experiments.